Myeloablative conditioning regimens for AML allografts: 30 years later.
During the last three decades, several myeloablative conditioning regimens have been used for AML allografts. In this review, we systematically examine the data from studies reporting on myeloablative conditioning regimens for AML allografts. High-dose busulfan combined with cyclophosphamide (BuCy) and cyclophosphamide in combination with total body irradiation (CyTBI) are the two most commonly used conditioning regimens for AML allografts. From the available data, there are no significant differences in survival with these two regimens. A small benefit of decreased relapse rate with CyTBI is counterbalanced by a nonsignificant increase in treatment-related mortality. The incidence of veno-occlusive disease is significantly higher in patients treated with BuCy. Therapeutic monitoring of busulfan was not reported in any of the studies comparing the regimens. Either of the regimens can be used for AML allografts, and the choice may ultimately depend on local availability and expertise. Further improvements may be possible from modifications of the standard regimens. Data from these latter studies seem to be encouraging, but are not based on comparative randomized trials.
Department of Medical Oncology and Hematology, Princess Margaret Hospital/Ontario Cancer Institute, Room 5-224, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9. vikas.gupta@uhn.on.ca
V
V
Gupta
H M
HM
Lazarus
A
A
Keating
D000208:Acute Disease; D016026:Bone Marrow Transplantation / Q000379:methods*; D003131:Combined Modality Therapy; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D019653:Myeloablative Agonists / Q000627:therapeutic use*; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous
D019653:Myeloablative Agonists